StockNews.com started coverage on shares of InspireMD (NYSE:NSPR – Free Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.
Several other brokerages also recently commented on NSPR. Piper Sandler restated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a research note on Tuesday, September 17th. Lake Street Capital started coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock.
Get Our Latest Stock Report on NSPR
InspireMD Stock Performance
InspireMD (NYSE:NSPR – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The firm had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter last year, the company earned ($0.15) earnings per share. Sell-side analysts forecast that InspireMD will post -0.79 EPS for the current year.
Institutional Trading of InspireMD
An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by institutional investors and hedge funds.
About InspireMD
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Read More
- Five stocks we like better than InspireMD
- Consumer Staples Stocks, Explained
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- What Are Growth Stocks and Investing in Them
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- 3 Tickers Leading a Meme Stock Revival
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.